Jazz Pharmaceuticals Proactively Engages Investors at Upcoming Major Conferences

Upcoming Investor Conferences by Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in several significant investor conferences scheduled throughout September 2026. These events provide an excellent opportunity for the company to engage with the investment community and keep them informed about its strategic initiatives, drug development progress, and future outlook.

The conferences include:

1. Wells Fargo 21st Annual Healthcare Conference
Date: September 9, 2026
Time: 1:30 PM ET

2. Citi 2026 Biopharma Back to School Summit
Date: September 10, 2026
Time: 10:40 AM ET

3. Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 15, 2026
Time: 12:20 PM ET

4. Deutsche Bank Healthcare Summit
Date: September 16, 2026
Time: 8:00 AM ET

These sessions, designed in a fireside chat format, not only allow investors to hear directly from the company's management but also provide a platform for discussing crucial topics related to Jazz Pharmaceuticals' innovative approaches and advancements in biopharmaceuticals.

The audio webcasts for these fireside chats will be accessible through the Investors section of the Jazz Pharmaceuticals website, enabling broader access to stakeholders unable to attend in person. Recorded sessions will remain available for replay for 30 days following the events, ensuring that all interested parties can review the discussions at their convenience.

About Jazz Pharmaceuticals

Founded to innovate and transform the lives of patients and their families, Jazz Pharmaceuticals is driven by a commitment to develop effective treatments for patients suffering from rare diseases. The company’s portfolio includes therapies for a range of conditions, such as epilepsy, various cancers, and sleep disorders, representing an array of vital healthcare solutions aiding individuals in need.

Jazz Pharmaceuticals prides itself on a patient-focused approach embedded in its research and development strategy. This model catalyzes pioneering advancements in the therapeutic space and underscores its commitment to the global healthcare community. With its headquarters located in Dublin, Ireland, the company operates research and development laboratories and manufacturing facilities across multiple locations worldwide, fostering a dedicated network to serve patients globally.

As Jazz Pharmaceuticals anticipates the upcoming conferences, it looks forward to not only sharing their progress but also reaffirming its commitment to patient-centric healthcare solutions. The insights exchanged during these discussions are part of the broader dialogue between stakeholders and the company, fostering transparent communication that is crucial in today’s healthcare landscape.

For more detailed insights about the company and the upcoming investor events, please visit Jazz Pharmaceuticals’ official investor relations site.